Corneal deposits associated with topical tosufloxacin following penetrating keratoplasty: a case report
Authors Katahira H, Kumakura S, Hattori T, Goto H
Received 17 January 2017
Accepted for publication 28 March 2017
Published 13 July 2017 Volume 2017:10 Pages 239—241
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 3
Editor who approved publication: Dr Scott Fraser
Haruki Katahira, Shigeto Kumakura, Takaaki Hattori, Hiroshi Goto
Department of Ophthalmology, Tokyo Medical University, Shinjukuku, Tokyo, Japan
Purpose: To report the adverse event of topical tosufloxacin administered after penetrating keratoplasty in one patient.
Case report: A 60-year-old female was referred to our hospital for treatment of vision loss due to corneal opacification, etiology was unknown. Slit lamp examination showed dense opacification in corneal stroma. Penetrating keratoplasty was performed on her left eye. She was treated with topical applications of 1.5% levofloxacin, 0.5% cefmenoxime, 0.1% betamethasone, 0.1% hyaluronate sodium, and 3% aciclovir after penetrating keratoplasty. Delayed epithelialization of the donor graft was observed at day 4 post-transplantation. Because of the concern that levofloxacin induced corneal epithelialization delay, 1.5% levofloxacin was changed to 0.3% tosufloxacin. At day 6 post-transplantation, deposits on the epithelial defect of the donor graft were observed. Tosufloxacin was suspected to be the cause of deposits, and tosufloxacin eye drop was discontinued. The deposits decreased gradually and completely disappeared by 5 months post-transplantation.
Conclusion: Topical tosufloxacin treatment has the risk of precipitation on compromised corneas such as corneal grafts with epithelial defect after penetrating keratoplasty. After discontinuation of therapy, the deposit may resolve spontaneously without surgical removal.
Keywords: corneal deposit, tosufloxacin, penetrating keratoplasty
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]